





CERTIFICATE OF ANALYSIS No.: 2021-3935

CLIENT

SYNERGIA Pharmaceuticals, s.r.o., Varsavska 36 12000 Praha, Czech Republic

SAMPLE

Cannabis Clinical CBG + CBD 20%





Sample condition:	SUITABLE	Work order:	2021-104894	Sample received:	12/03/2021
Sample ID:	211064	Analysis ID:	2021_057	Start of analysis:	12/03/2021
Sample type:	Viscous liquid	Method ID:	PHL_RPC_12C	End of analysis:	15/03/2021
Batch No.:	CBG+CBD20-2021-03	Method SOP:	MET-002	Analyst:	Aleksander Jefim

CANNABINOID PROFILE	Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV - Cannabidivarin	0.336	0.061	<u> </u>
CBDA - Cannabidiolic acid	< LOQ	n/a	
CBGA - Cannabigerolic acid	< LOQ	n/a	
CBG - Cannabigerol	15.1	1.1	
CBD - Cannabidiol	5.79	0.29	
THCV - Tetrahydrocannabivarin	< LOQ	n/a	
CBN - Cannabinol	< LOQ	n/a	
CBC - Cannabichromene	0.281	0.048	<u> </u>
THC - Δ-9-Tetrahydrocannabinol	0.194	0.033	<u> </u>
THCA - Δ-9-Tetrahydocannabinolic acid	< LOQ	n/a	
8-THC - Δ-8-Tetrahydrocannabinol *	< LOQ	n/a	
CBL - Cannabicyclol *	0.0415	0.0091	

The results marked by * relate to non-accredited activity.

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:	Approved by:	Authorized by:
	\mathcal{I}	Jan Tate
16/03/2021	Muyn	
	mag. Marko Dragan	dr. Boštjan Jančar
	Analytical Laboratory Manager	Chief Technology Officer
End of Cartificate		